Literature DB >> 16707363

Diagnostic assays for the JAK2 V617F mutation in chronic myeloproliferative disorders.

Timothy C Greiner.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16707363     DOI: 10.1309/NXXT-GRCX-D0TM-A3C2

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


× No keyword cloud information.
  5 in total

1.  Design and evaluation of a real-time PCR assay for quantification of JAK2 V617F and wild-type JAK2 transcript levels in the clinical laboratory.

Authors:  Jason D Merker; Carol D Jones; Stephen T Oh; Iris Schrijver; Jason Gotlib; James L Zehnder
Journal:  J Mol Diagn       Date:  2009-12-03       Impact factor: 5.568

2.  Validating the Sensitivity of High-Resolution Melting Analysis for JAK2 V617F Mutation in the Clinical Setting.

Authors:  Chien-Yu Lin; Cheng-Mao Ho; Gevorg Tamamyan; Shu-Fen Yang; Ching-Tien Peng; Jan-Gowth Chang
Journal:  J Clin Lab Anal       Date:  2016-05-12       Impact factor: 2.352

3.  Amplification refractory mutation system, a highly sensitive and simple polymerase chain reaction assay, for the detection of JAK2 V617F mutation in chronic myeloproliferative disorders.

Authors:  Qiaofang Chen; Pin Lu; Amy V Jones; Nicholas C P Cross; Richard T Silver; Y Lynn Wang
Journal:  J Mol Diagn       Date:  2007-04       Impact factor: 5.568

4.  Detection of the Janus kinase 2 V617F mutation using a locked nucleic-acid, real-time polymerase chain reaction assay.

Authors:  Tshiphiri Senamela; Marleen Kock; Piet Becker; Joachim J C Potgieter
Journal:  Afr J Lab Med       Date:  2018-01-31

5.  Comparative study of different methodologies to detect the JAK2 V617F mutation in chronic BCR-ABL1 negative myeloproliferative neoplasms.

Authors:  Alline Didone; Luciana Nardinelli; Mariana Marchiani; Antonio Roberto Lancha Ruiz; Ariel Lais de Lima Costa; Ismael Severino Lima; Nathalia Moreira Santos; Sabri Saeed Sanabani; Israel Bendit
Journal:  Pract Lab Med       Date:  2015-12-14
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.